cbd

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent results from…

Robin Lefferts
November 20, 2024

Healthcare Stocks

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the…

Ryan Allway
November 18, 2024

California Extract Experts Going Vertical with 187 Acres of Canopy

From an investor’s perspective, the cannabis industry has had a rough go…

Robin Lefferts
November 14, 2024

Cardiol Therapeutics Advancing Orphan Drug Trial to Phase 2/3

Clinical trials are crucial for smaller pharma companies. While the ultimate aim…

Robin Lefferts
October 28, 2024

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1…

Ryan Allway
October 22, 2024

Healthcare Stocks

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the…

Ryan Allway
September 10, 2024

Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics

The future of smaller drug development companies frequently hinges on the results…

Robin Lefferts
June 20, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy…

Ryan Allway
June 13, 2024

Near-Term Catalysts on the Horizon for Cardiol Therapeutics

Investing in smaller drug development companies requires patience. The journey from discovery…

Robin Lefferts
May 28, 2024

Healthcare Stocks

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on…

Ryan Allway
May 15, 2024

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

California Extract Experts Going Vertical with 187 Acres of Canopy

Cardiol Therapeutics Advancing Orphan Drug Trial to Phase 2/3

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Near-Term Catalysts on the Horizon for Cardiol Therapeutics

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Don Kreski

Robin Lefferts

Ryan Allway

LEEF Brands Inc. Closes Second Tranche Private Placement Financing Round of CAD$500,000

LEEF Brands Moves Treasury into Bitcoin, Profits $73k in Weeks

LEEF Brands to Become One of the First Publicly Traded Cannabis Company to Integrate Bitcoin into its Treasury Reserve via US$5 Million Bitcoin-Backed Debenture Offering

LEEF Brands Inc. Closes Private Placement Financing Round of CAD$2,118,375

Sign Up for Our Newsletter